DKK 802.5
(0.44%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 323.61 Million DKK | 303.02% |
2022 | 73.27 Million DKK | -57.83% |
2021 | 173.75 Million DKK | -33.87% |
2020 | 262.74 Million DKK | 542.14% |
2019 | 40.91 Million DKK | 128.76% |
2018 | -142.26 Million DKK | -213.68% |
2017 | 125.14 Million DKK | -38.45% |
2016 | 203.31 Million DKK | 22.92% |
2015 | 165.41 Million DKK | 18.15% |
2014 | 139.99 Million DKK | 2355.23% |
2013 | 5.7 Million DKK | -97.25% |
2012 | 207.63 Million DKK | 46.04% |
2011 | 142.17 Million DKK | 62.75% |
2010 | 87.35 Million DKK | 245.03% |
2009 | 25.31 Million DKK | -55.0% |
2008 | 56.26 Million DKK | -6.11% |
2007 | 59.92 Million DKK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 17.87 Million DKK | 536.09% |
2024 Q1 | 3.87 Million DKK | -58.0% |
2023 Q4 | 9.22 Million DKK | -96.82% |
2023 FY | 295.31 Million DKK | 303.02% |
2023 Q2 | 5.2 Million DKK | 104.28% |
2023 Q3 | 290.35 Million DKK | 5478.39% |
2023 Q1 | -121.57 Million DKK | -596.18% |
2022 Q2 | 26.03 Million DKK | 113.98% |
2022 Q4 | 24.5 Million DKK | -43.2% |
2022 FY | 73.27 Million DKK | -57.83% |
2022 Q1 | 12.16 Million DKK | -59.69% |
2022 Q3 | 43.13 Million DKK | 65.71% |
2021 Q4 | 30.17 Million DKK | -61.18% |
2021 Q1 | 24.07 Million DKK | -31.38% |
2021 Q3 | 77.73 Million DKK | 86.12% |
2021 FY | 173.75 Million DKK | -33.87% |
2021 Q2 | 41.76 Million DKK | 73.47% |
2020 FY | 262.74 Million DKK | 542.14% |
2020 Q2 | 192.99 Million DKK | 1454.24% |
2020 Q3 | 22.25 Million DKK | -88.47% |
2020 Q4 | 35.08 Million DKK | 57.66% |
2020 Q1 | 12.41 Million DKK | 8.04% |
2019 Q3 | 9.69 Million DKK | -50.89% |
2019 Q4 | 11.49 Million DKK | 18.59% |
2019 FY | 40.91 Million DKK | 128.76% |
2019 Q1 | - DKK | 100.0% |
2019 Q2 | 19.73 Million DKK | 0.0% |
2018 Q2 | 13.09 Million DKK | 39.78% |
2018 FY | -142.26 Million DKK | -213.68% |
2018 Q1 | 9.36 Million DKK | -3.96% |
2018 Q4 | -163.76 Million DKK | 0.0% |
2018 Q3 | - DKK | -100.0% |
2017 Q2 | 9.56 Million DKK | -85.75% |
2017 FY | 125.14 Million DKK | -38.45% |
2017 Q3 | 38.68 Million DKK | 304.26% |
2017 Q4 | 9.75 Million DKK | -74.79% |
2017 Q1 | 67.14 Million DKK | -57.0% |
2016 Q4 | 156.13 Million DKK | 355.76% |
2016 Q1 | 5.63 Million DKK | -96.18% |
2016 FY | 203.31 Million DKK | 22.92% |
2016 Q3 | 34.25 Million DKK | 383.2% |
2016 Q2 | 7.09 Million DKK | 25.82% |
2015 Q2 | 6.14 Million DKK | 11.96% |
2015 FY | 165.41 Million DKK | 18.15% |
2015 Q1 | 5.48 Million DKK | 1.74% |
2015 Q4 | 147.56 Million DKK | 2273.21% |
2015 Q3 | 6.21 Million DKK | 1.25% |
2014 Q3 | 57.37 Million DKK | 1445.11% |
2014 Q2 | 3.71 Million DKK | -94.95% |
2014 Q1 | 73.52 Million DKK | 2564.84% |
2014 FY | 139.99 Million DKK | 2355.23% |
2014 Q4 | 5.39 Million DKK | -90.6% |
2013 Q3 | 2 Million DKK | 115.1% |
2013 Q2 | 934 Thousand DKK | 0.0% |
2013 Q1 | - DKK | 100.0% |
2013 FY | 5.7 Million DKK | -97.25% |
2013 Q4 | 2.75 Million DKK | 37.33% |
2012 Q3 | 37.36 Million DKK | -43.06% |
2012 FY | 207.63 Million DKK | 46.04% |
2012 Q4 | -372 Thousand DKK | -101.0% |
2012 Q1 | 105.01 Million DKK | 370.57% |
2012 Q2 | 65.62 Million DKK | -37.51% |
2011 Q3 | 670 Thousand DKK | -99.44% |
2011 Q1 | - DKK | -100.0% |
2011 FY | 142.17 Million DKK | 62.75% |
2011 Q4 | 22.31 Million DKK | 3230.75% |
2011 Q2 | 119.29 Million DKK | 0.0% |
2010 Q1 | - DKK | 0.0% |
2010 Q4 | 3.72 Million DKK | 376.6% |
2010 Q3 | 782 Thousand DKK | -99.06% |
2010 Q2 | 82.84 Million DKK | 0.0% |
2010 FY | 87.35 Million DKK | 245.03% |
2009 FY | 25.31 Million DKK | -55.0% |
2008 FY | 56.26 Million DKK | -6.11% |
2007 FY | 59.92 Million DKK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ALK-Abelló A/S | 3.03 Billion DKK | 89.337% |
Bavarian Nordic A/S | 4.52 Billion DKK | 92.843% |
Genmab A/S | 16.24 Billion DKK | 98.008% |
Gubra A/S | 114.93 Million DKK | -181.56% |
Novo Nordisk A/S | 196.49 Billion DKK | 99.835% |
Orphazyme A/S | - DKK | -Infinity% |
Pharma Equity Group A/S | -480 Thousand DKK | 67519.583% |